p14ARF modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53

Cancer Research

Volumn 61, Issue 16, 2001, Pages 5959-5963

  Yang, Cheng Ta ^a,b   You, Liang ^b   Uematsu, Kazutsugu ^b   Yeh, Che Chung ^c   McCormick, Frank ^b   Jablons, David M ^b  

^a Chang Gung Memorial Hospital   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS; PROTEIN P53; VIRUS VECTOR;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; CYTOSTASIS; GENE LOCUS; GENE THERAPY; HUMAN; HUMAN CELL; MESOTHELIOMA; PRIORITY JOURNAL; VIRUS REPLICATION;

ADENOVIRUS E1B PROTEINS; ADENOVIRUSES, HUMAN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYTOPATHOGENIC EFFECT, VIRAL; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035881594     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Mesothelioma clinical presentation
2. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
3. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary, cultures freshly made from lung cancer patients
4. Absence of p53 mutations in malignant mesotheliomas
5. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma
6. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma
7. The INK4a/ARF tumor suppressor: One gene-two products-two pathways
8. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells
9. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
10. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
11. Mdm2: Keeping p53 under control
12. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53
13. Establishment of human mesothelioma cell lines (MS-1, -2) and production of a monoclonal antibody (anti-MS) with diagnostic and therapeutic potential
14. A simplified system for generating recombinant adenoviruses
15. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells
16. Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells
17. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression
18. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector
19. Cancer cell cycles
20. Cancer therapy based on p53
21. ONYX-015, an EIB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
22. Regulation of p53 function
23. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015)
24. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2